Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner


Özyurt H., Yildirim Z., Kotuk M., YILMAZ H. İ., Yaǧmurca M., Iraz M., ...More

Journal of Applied Toxicology, vol.24, no.4, pp.269-275, 2004 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2004
  • Doi Number: 10.1002/jat.983
  • Journal Name: Journal of Applied Toxicology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.269-275
  • Keywords: Cisplatin, Erdosteine, Renal failure
  • Hatay Mustafa Kemal University Affiliated: Yes

Abstract

The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity. Three different doses of erdosteine at 25,50 and 75 mg kg-1 were studied in rats. Intraperitoneal administration of 7 mg kg-1 cisplatin led to acute renal failure, as indicated by kidney histology and increases in plasma creatinine and blood urea nitrogen (BUN) levels. At 5 days after cisplatin injection the BUN level was increased significantly from 15.1 ± 4.3 to 126.7 ± 152.6 mg dl-1 and plasma creatinine levels increased from 0.37 ± 0.005 to 1.68 ± 1.9 mg dl-1. When the rats were administered 50 and 75 mg kg-1 erdosteine 24 h before cisplatin injection that was continued until sacrifice (total of 6 days), the BUN and creatinine levels remained similar to control levels and the grade of histology was similar. Erdosteine at doses of 50 and 75 mg kg-1 ameliorates cisplatin-induced renal failure. The optimum dose of erdosteine may be 50 mg kg-1 in this study. Copyright © 2004 John Wiley & Sons, Ltd.